ClinicalTrials.gg
CompletedNCT00319020FUTURE 2Updated Feb 4, 2025Results posted

Bosentan in Children With Pulmonary Arterial Hypertension Extension Study

A Phase 3 interventional study of Bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2005, registered Apr 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
11th of 18
33 · median 37
Started
2005
with 1 other
Phase 3
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 2 that started in 2005, is one of 7 in phase 3, and was the 5th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • bosentan
  • pulmonary arterial hypertension
  • children
  • FUTURE 1
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed by the parents or the legal representatives.
  • Patients who completed the FUTURE 1 study.
  • Patients who tolerated bosentan pediatric formulation and for whom bosentan is considered beneficial at the end of FUTURE 1.
  • Males or females >= 2 and \< 12 years of age at enrollment in FUTURE 2 (this study). Females who are menstruating must have a negative pregnancy test. A reliable method of must be considered, if appropriate.

Exclusion criteria

Exclusion Criteria:

  • Intolerance to bosentan despite dose reductions.
  • Any laboratory abnormality that precludes continuation of bosentan therapy.
  • Pregnancy or breast-feeding.
  • Known to bosentan or any of the .
  • Premature and permanent study drug discontinuation during FUTURE 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Bosentan

    Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.

    Drug: Bosentan

Interventions

  • 32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally

    Also known as: Ro 47-0203, Tracleer

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Study (EOS) in Height for Age.

    In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula: Z-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population

    Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average

  2. Change From Baseline to End of Study (EOS) in Body Weight

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.

    Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average

  3. Change From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP)

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.

    Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average

  4. Change From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP)

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.

    Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average

  5. Change From Baseline to End of Study (EOS) in Pulse Rate

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.

    Time frame: From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average

  6. Proportion of Patients With Treatment-emergent Liver Function Abnormalities

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes. Proportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.

    Time frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average

  7. Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities

    The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities. Proportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.

    Time frame: After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average

  8. Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment

    Time frame: From the first study drug administration in FUTURE 1, for an average of 31 months

07

Results

Posted Mar 29, 2017

Participant flow

36 Children ( \>= 2 years and \< 12 years) with idiopathic or familial pulmonary arterial hypertension were recruited from 11 centers across Europe and USA and enrolled in the FUTURE 1 trial (baseline). Only patients who completed FUTURE 1 (n=34) could be enrolled in FUTURE 2. Enrollment in FUTURE 2 started August 23, 2005.

Participant flow — Overall Study
MilestonePatients With Previous BosentanBosentan-naive Patients
Started1521
Enrollment in future 2 (f-2)1320
Completed88
Not completed713
Withdrew: Death22
Withdrew: Withdrawal by subject41
Withdrew: F-1 completed but not enrolled in f-210
Withdrew: Administrative reason05
Withdrew: Disease progression02
Withdrew: Transplant01
Withdrew: Treatment failure01
Withdrew: Adverse event01

Outcome measures

PrimaryChange From Baseline to End of Study (EOS) in Height for Age.

In order to compare the growth data with those of healthy children, growth curves are calculated from height data collected throughout the follow-up period. For each patient, height measured at each study visit was converted to a z-score and expressed in standard deviations (SD) from WHO growth standards. The Z-score was calculated according to the following formula: Z-score = (observed value of the study participant - median value of the reference population) / SD value of the reference population

Time frame:
From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Reported as:
Median · Z-score
Change From Baseline to End of Study (EOS) in Height for Age.
Z-scorePatients With Previous BosentanBosentan-naive PatientsTotal
Z-score at baseline-0.8 (-3.32 to 3.72)0.32 (-2.62 to 1.99)-0.64 (-3.32 to 3.72)
Z-score at EOS-0.74 (-3.52 to 2.78)-0.08 (-2.44 to 1.84)-0.36 (-3.52 to 2.78)
Z-score change from baseline to EOS-0.05 (-0.94 to 0.91)-0.01 (-0.77 to 1.08)-0.01 (-0.94 to 1.08)
PrimaryChange From Baseline to End of Study (EOS) in Body Weight

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including growth as measured by changes from baseline in body weight and height.

Time frame:
From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Reported as:
Median · kg
Change From Baseline to End of Study (EOS) in Body Weight
kgPatients With Previous BosentanBosentan-naive PatientsTotal
Weight at baseline19.6 (12.5 to 30.2)21.6 (11 to 39)19.6 (11 to 39)
Weight change from baseline to EOS8.2 (5 to 24.8)8.5 (1.8 to 18.5)8.3 (1.8 to 24.8)
PrimaryChange From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP)

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.

Time frame:
From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Reported as:
Median · mmHg
Change From Baseline to End of Study (EOS) in Systolic Blood Pressure (SBP)
mmHgPatients With Previous BosentanBosentan-naive PatientsTotal
SBP at baseline101.5 (87 to 115)104 (79 to 121)102.5 (79 to 121)
SBP change from baseline to EOS-10.5 (-20 to 25)4 (-21 to 28)-4.5 (-21 to 28)
PrimaryChange From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP)

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in blood pressure.

Time frame:
From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Reported as:
Median · mmHg
Change From Baseline to End of Study (EOS) in Diastolic Blood Pressure (DBP)
mmHgPatients With Previous BosentanBosentan-naive PatientsTotal
DBP at baseline54.5 (47 to 94)60 (52 to 75)59 (47 to 94)
DBP change from baseline to EOS-5 (-34 to 19)-2 (-13 to 20)-3 (-34 to 20)
PrimaryChange From Baseline to End of Study (EOS) in Pulse Rate

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including changes from baseline in pulse rate.

Time frame:
From baseline (FUTURE 1) up to 28 days after study treatment discontinuation (EOS or premature study treatment discontinuation), i.e. 32 months in average
Reported as:
Median · Beats per minutes
Change From Baseline to End of Study (EOS) in Pulse Rate
Beats per minutesPatients With Previous BosentanBosentan-naive PatientsTotal
Pulse rate at baseline87 (55 to 118)94.5 (62 to 133)88 (55 to 133)
Pulse rate change from baseline to EOS-11 (-46 to 36)-10 (-30 to 11)-11 (-46 to 36)
PrimaryProportion of Patients With Treatment-emergent Liver Function Abnormalities

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including laboratory abnormalities related to liver enzymes. Proportion of patients with increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN) is reported here.

Time frame:
After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average
Reported as:
Number · Percentage of participants
Proportion of Patients With Treatment-emergent Liver Function Abnormalities
Percentage of participantsPatients With Previous BosentanBosentan-naive PatientsTotal
ALT > 3 x ULN04.82.8
AST > 3 x ULN04.82.8
PrimaryProportion of Patients With Treatment-emergent Hemoglobin Abnormalities

The main study objective was to assess the long-term safety and tolerability of bosentan in children with PAH, including hemoglobin abnormalities. Proportion of patients with marked hemoglobin decreases (i.e., decrease of or above 15% of the lower normal limit (LL)) is reported here.

Time frame:
After baseline, up to 1 calendar day after study treatment discontinuation in FUTURE 1 or FUTURE 2, i.e. 31 months in average
Reported as:
Number · Percentage of participants
Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities
Percentage of participantsPatients With Previous BosentanBosentan-naive PatientsTotal
Proportion of Patients With Treatment-emergent Hemoglobin Abnormalities13.39.511.1
PrimaryNumber of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment
Time frame:
From the first study drug administration in FUTURE 1, for an average of 31 months
Reported as:
Number · Participants
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment
ParticipantsPatients With Previous BosentanBosentan-naive PatientsTotal
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Study Treatment156

Adverse events

Collected over From the first administration of study treatment and for an average of 31 months for frequent adverse events (up to 1 day after study treatment discontinuation), and for an average of 32 months (up to 28 days after study treatment discontinuation) for serious adverse events. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Previous Bosentan—9/15 (60%)12/15 (80%)
Bosentan_naive Patients—9/21 (42.9%)16/21 (76.2%)
Single Arm Bosentan_Total—18/36 (50%)26/36 (72.2%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPatients With Previous BosentanBosentan_naive PatientsSingle Arm Bosentan_Total
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders2/151/213/36
DEVICE RELATED INFECTIONInfections and infestations1/152/213/36
PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders1/152/213/36
ABDOMINAL PAINGastrointestinal disorders1/150/211/36
ADENOIDECTOMYSurgical and medical procedures1/150/211/36
BACTERAEMIAInfections and infestations1/150/211/36
BRONCHIAL OBSTRUCTIONRespiratory, thoracic and mediastinal disorders1/150/211/36
CATHETER SITE INFECTIONInfections and infestations1/150/211/36
CHEST PAINGeneral disorders1/150/211/36
CONVULSIONNervous system disorders1/150/211/36
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPatients With Previous BosentanBosentan_naive PatientsSingle Arm Bosentan_Total
ABDOMINAL PAINGastrointestinal disorders1/155/216/36
NASOPHARYNGITISInfections and infestations3/154/217/36
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders3/151/214/36
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/154/215/36
VOMITINGGastrointestinal disorders0/154/214/36
ABDOMINAL PAIN UPPERGastrointestinal disorders0/153/213/36
BRONCHITISInfections and infestations2/153/215/36
CHEST PAINGeneral disorders0/153/213/36
FLUSHINGVascular disorders1/153/214/36
HEADACHENervous system disorders1/153/214/36

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Patients With Previous BosentanBosentan-naive PatientsTotal
Median7 (3 to 10)7 (2 to 11)7 (2 to 11)
Age, Customized
Age, Customized(Participants)Patients With Previous BosentanBosentan-naive PatientsTotal
2-3 years old134
4-5 years old369
6-11 years old111223
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Previous BosentanBosentan-naive PatientsTotal
Female51015
Male101121
Etiology of pulmonary arterial hypertension (PAH)
Etiology of pulmonary arterial hypertension (PAH)(Participants)Patients With Previous BosentanBosentan-naive PatientsTotal
Idiopathic PAH121931
Familial PAH325
Duration of pulmonary arterial hypertension (PAH)
Duration of pulmonary arterial hypertension (PAH)(Months)Patients With Previous BosentanBosentan-naive PatientsTotal
Median37.6 (1.2 to 82.6)14 (0 to 133.5)25.8 (0 to 133.5)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galie N, Ivy DD, Jais X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 1;202:52-8. doi: 10.1016/j.ijcard.2015.08.080. Epub 2015 Aug 9. Erratum In: Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. PubMed 26386921 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2005 to primary completion in Oct 2011, 74 months.

Results were first posted in Mar 2017, 5 years 5 months after primary completion. A results delay was requested in Mar 2012.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 74 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2006
First posted
Apr 27, 2006
StartActual
Aug 23, 2005
Primary completionActual
Oct 28, 2011
CompletionActual
Oct 28, 2011
Results delay requested
Mar 9, 2012
Results first posted
Mar 29, 2017
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00319020
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Aug 23, 2005
Primary completion
Oct 28, 2011
Completion
Oct 28, 2011
Results posted
Mar 29, 2017
Last update
Feb 4, 2025

Study contacts

Andjela Kusic-Pajic, MD
study director · Actelion

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion